ACAD NASDAQ
Acadia Pharmaceuticals Inc.
1W: -0.3%
1M: -4.5%
3M: -24.1%
YTD: -24.9%
1Y: -9.2%
3Y: -13.9%
5Y: +12.2%
$20.17
+0.43 (+2.18%)
After Hours: $20.23 (+0.05, +0.27%)
Weekly Expected Move ±4.8%
$18
$19
$20
$21
$22
Credit Risk of going bust: lower than 86% of companies Debt: 2.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.04 (down 99.8%), Acadia Pharmaceuticals Inc. would be worth roughly what it owes.
Total debt $73.9M against a stock market value of $3.40B.
Distance to default 11.64 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $36.9M (short-term plus half of long-term), stock volatility 39.1%; Altman Z'' 3.47. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.04 (down 99.8%), Acadia Pharmaceuticals Inc. would be worth roughly what it owes.
Total debt $73.9M against a stock market value of $3.40B.
Distance to default 11.64 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $36.9M (short-term plus half of long-term), stock volatility 39.1%; Altman Z'' 3.47. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
9 relationships8
As Filer
counterparties named
1
As Counterparty
mentioned by others
2
Rel. Types
2022-01-10
Earliest Filing
2025-05-20
Latest Filing
partner: 6
supplier: 2
Counterparties (Filed by ACAD)
8 relationshipsCompanies named in ACAD's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| 210 Associates Limited Partnership | — | supplier | Landlord for the 210 Carnegie Center office lease | 2025-05-20 | View |
| Boston Properties | — | supplier | Landlord for the 502 Carnegie Center office lease | 2025-05-20 | View |
| Aurobindo Pharma Limited | — | partner | Defendant in patent infringement litigation | 2025-05-20 | View |
| Aurobindo Pharma USA, Inc. | — | partner | Affiliate of Aurobindo Pharma Limited involved in litigation | 2025-05-20 | View |
| MSN Laboratories Private Ltd. | — | partner | Defendant in patent infringement litigation | 2025-05-20 | View |
| MSN Pharmaceuticals, Inc. | — | partner | Affiliate of MSN Laboratories Private Ltd. involved in litigation | 2025-05-20 | View |
| Neuren Pharmaceuticals Limited | — | partner | Joint Venture and License Agreement partner receiving one-third of net proceeds from PRV sale. | 2024-12-11 | View |
| Neuren Pharmaceuticals Limited | — | partner | Joint venture and license agreement for global commercialization and development of trofinetide and NNZ-2591 | 2023-07-18 | View |
Mentioned As Counterparty
1 mentionsOther companies that named ACAD in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-23 | Officer/Director Change | View | |
| 2026-09-24 | Regulation FD; Other Events; Exhibits | View | |
| 2026-09-11 | Other Events; Exhibits | View | |
| 2026-08-04 | Earnings Release; Exhibits | View | |
| 2026-05-29 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-06 | Earnings Release; Exhibits | View | |
| 2026-05-01 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-03-05 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-02-25 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-13 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-03 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-10 | Other Events | View | |
| 2025-05-29 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-20 | Entry into Material Definitive Agreement; Other Events | Agreement | View |
| 2025-05-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-16 | Amendments to Articles of Incorporation or Bylaws; Financial Statements and Exhibits | View | |
| 2025-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-12-11 | Completion of Acquisition or Disposition of Assets | Acquisition | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR